AMD and PsiQuantum Expand Their Partnership in Quantum Computing

The race to develop commercially useful quantum computers is increasingly becoming a challenge of connecting unfamiliar technologies with the computing infrastructure that already supports modern industry. AMD and PsiQuantum have announced an expanded partnership intended to address that problem, combining conventional processors, artificial intelligence hardware and silicon-photonics technology in systems designed for large-scale quantum computing. AMD also plans to make an equity investment in PsiQuantum, although the companies have not disclosed the amount. The agreement reflects growing interest in technologies that could eventually tackle scientific and commercial calculations beyond the practical capabilities of conventional computers, while recognising that quantum systems will still depend heavily on established computing technologies.

PsiQuantum is developing an approach to quantum computing based on photonics, using particles of light as part of its computing architecture. Its technology draws on semiconductor manufacturing processes and optical networking, creating opportunities to integrate quantum components with conventional computing systems. AMD will contribute central processing units, graphics processors, adaptive computing technology and software expertise. The collaboration is intended to support the demanding tasks required to operate large quantum computers, including error correction and the processing of information exchanged between quantum and classical systems. These functions are essential because quantum devices are highly sensitive to errors and require sophisticated supporting infrastructure.

The partnership also includes research into applications that combine quantum computing with high-performance computing and artificial intelligence. Drug discovery is an early area of interest, with the companies reporting progress in simulations involving covalent inhibitors, a class of molecules relevant to oncology research. Such work may eventually contribute to more detailed modelling of molecular behaviour, although the results should not be interpreted as proof that commercially useful quantum drug discovery has already arrived. The companies have also discussed the possibility of extending their collaboration through the Illinois Quantum and Microelectronics Park, where PsiQuantum is an anchor tenant. The investment amount, implementation schedule and eventual commercial outcomes remain undisclosed.

The broader significance lies in the recognition that quantum computing will not develop in isolation from the semiconductor and AI industries. Even highly advanced quantum processors require conventional systems to control operations, process data and translate results into useful applications. That creates opportunities for established technology companies to participate in quantum development without producing quantum processors themselves. AMD's partnership with PsiQuantum illustrates how the boundaries between computing disciplines are becoming increasingly interconnected. For investors, the announcement offers evidence of continuing commercial interest in the field, but the industry's central challenge remains unresolved: translating scientific advances into reliable systems capable of delivering measurable advantages for real-world customers.